Pharmacovigilance Services for Biotech and Pharmaceutical Companies
Evestia Clinical provides integrated Pharmacovigilance expertise for biotechnology and pharmaceutical companies, delivering proactive safety oversight, regulatory confidence and successful product development from Phase I through post-marketing.
Pharmacovigilance Built Around Biotech Companies
Evestia Clinical delivers integrated safety leadership, operating as an extension of sponsor safety teams throughout clinical development. Sponsors gain direct access to experienced Pharmacovigilance professionals and senior medical safety leadership, providing proactive safety oversight, informed benefit-risk evaluation and the regulatory knowledge that supports confident program progression. Collaborative partnership means safety specialists engage proactively across every stage, building program knowledge and benefit-risk understanding that complex development requires.
This integrated approach connects Pharmacovigilance with Medical Affairs, Regulatory Affairs, Medical Writing and Clinical Operations within a single, coordinated governance structure. Safety oversight aligns with development timelines, regulatory objectives and the benefit-risk decisions that program success depends on, from first-in-human studies through to commercialization.
Experienced PV Specialists
Hands-on expertise across Phase I–IV & Post-Marketing and post-marketing safety activities, providing strategic guidance rather than administrative case processing.
Senior Safety Leadership
Sponsors work directly with experienced pharmacovigilance leaders throughout program delivery, not junior resource managed at a distance.
Global Regulatory Expertise
Coordinated safety strategies across FDA, EMA, MHRA and other key markets, maintaining compliance while navigating country-specific reporting requirements.
Flexible Support Models
Full-service PV delivery or embedded FSP specialists, scaled to program stage and sponsor requirements without permanent headcount expansion.
Pharmacovigilance Expertise
Integrated Pharmacovigilance across Phase I–IV & Post-Marketing development and post-marketing lifecycles, providing proactive safety oversight, informed benefit-risk evaluation and confident regulatory engagement through scalable, cross-functional solutions that strengthen program delivery at every stage.
Phase I–IV
Safety Management
Supporting clinical development
Post-Marketing
Safety Surveillance
Product lifecycle support
Global
Safety Reporting
Multi-region compliance expertise
Integrated
PV & Regulatory Expertise
Cross-functional safety oversight
Integrated Pharmacovigilance Supporting Confident Clinical Development
Integrated safety governance, proactive signal management and scalable Pharmacovigilance are central to confident clinical development. Sponsors gain the regulatory confidence, benefit-risk clarity and program insight that development decisions and regulatory submissions depend on throughout the product lifecycle.
Pharmacovigilance is delivered as a central integrated function within our Full-Service CRO model, working in close alignment with Medical Affairs, Clinical Operations, Regulatory Affairs and Medical Writing.
Why Pharmacovigilance Matters
Pharmacovigilance supports patient wellbeing, informs benefit-risk evaluation and builds regulatory confidence throughout the product lifecycle. Proactive safety oversight gives sponsors the evidence and assurance to advance programs confidently, supporting informed decisions at every development milestone.
Strong safety oversight supports better clinical decisions, strengthens regulatory submissions and builds the long-term safety evidence base that successful commercialization requires. Integrated Pharmacovigilance keeps sponsors well positioned to engage confidently with health authorities, attract investigator commitment and maintain the program credibility that boards, funds and partners expect.
From Phase I first-in-human studies through Phase II proof-of-concept and Phase III registration through to post-marketing surveillance, consistent, proactive Pharmacovigilance supports confident program progression and successful product development.
What Is Pharmacovigilance?
Pharmacovigilance is the continuous scientific discipline that supports patient wellbeing and informed benefit-risk evaluation throughout the product lifecycle. It enables confident benefit-risk decisions, supports regulatory confidence from early clinical development through commercialization, and provides the operational foundation for advancing programs with the safety data quality that health authorities expect.
Pharmacovigilance extends well beyond adverse event reporting. It is a strategic function that shapes development decisions, informs protocol amendments, supports regulatory submissions and underpins the long-term credibility of every medicinal product.
Pharmacovigilance activities include:
Integrated Pharmacovigilance supports patient wellbeing and informed benefit-risk evaluation while supporting regulatory compliance throughout development and commercialization.
The Value of Effective Safety Oversight
Integrated Pharmacovigilance supports more than regulatory compliance.
Strong safety oversight supports informed development decisions, regulatory confidence and continued trust with regulators, investigators and patients throughout the product lifecycle.
Our Pharmacovigilance Services
Each service contributes to program confidence, regulatory quality and patient wellbeing, coordinated within our integrated clinical development model.
Case Processing and Safety Reporting
Accurate, timely case processing provides the foundation for consistent global safety reporting and informed safety decision-making. Our teams manage the complete case lifecycle, ensuring every case is triaged, reviewed and submitted within required timeframes while maintaining the documentation quality that health authorities expect.
- Adverse Event processing
- Serious Adverse Event reporting
- Case triage
- Medical review coordination
- Follow-up management
- Regulatory submissions
Safety Database Management
Validated, well-maintained safety databases provide the operational foundation for compliant Pharmacovigilance. Sponsors can continue using their existing systems without disrupting established workflows. Our specialists operate across all leading safety platforms, within sponsor-owned systems, Evestia-hosted environments or hybrid models, providing the flexibility and technical depth that complex global programs require.
- Veeva Vault Safety
- Oracle Argus Safety
- ARIS Global LifeSphere Safety Multivigilance
Signal Detection and Safety Surveillance
Continuous signal detection provides timely safety insight that supports benefit-risk evaluation and confident program decisions. Our surveillance activities give sponsors the structured, continuous oversight needed to act early, inform benefit-risk decisions and support program momentum throughout development.
- Signal detection
- Signal validation
- Trend analysis
- Safety surveillance
- Risk assessment support
Aggregate Safety Reporting
High-quality aggregate safety reports demonstrate scientific rigor, regulatory consistency and a well-understood product safety profile. DSURs, PSURs and PBRERs are among the most important submissions sponsors make. Our teams prepare aggregate reports in close collaboration with Medical Writing and Regulatory Affairs specialists, ensuring scientific quality, regulatory compliance and consistent messaging across every submission.
- Development Safety Update Reports (DSURs)
- Periodic Safety Update Reports (PSURs)
- Periodic Benefit-Risk Evaluation Reports (PBRERs)
- Annual safety reports
- Safety summaries
Post-Marketing Pharmacovigilance
Post-marketing Pharmacovigilance extends safety oversight throughout commercialization, supporting ongoing patient wellbeing and regulatory compliance. Regulatory approval brings new safety obligations and ongoing surveillance responsibilities. Our post-marketing services provide the case management, signal oversight and aggregate reporting that keep marketed products compliant and commercially credible throughout the commercialization lifecycle.
- Case management
- Signal management
- Literature monitoring
- Risk management activities
- Local QPPV network support
- Safety reporting
Pharmacovigilance for Regulatory Compliance and Product Lifecycle Management
Cohesive regulatory submissions are built on consistent safety documentation. When Pharmacovigilance operates in close alignment with Medical Affairs, Regulatory Affairs and Medical Writing, safety data, scientific messaging and regulatory submissions stay consistent throughout the lifecycle. Integrated delivery ensures DSURs, PSURs, PBRERs and ICSRs are prepared within the same scientific framework, supporting aligned safety data and confident regulatory engagement.
At Evestia Clinical, Pharmacovigilance, Medical Affairs, Regulatory Affairs, Medical Writing and Clinical Operations function as a single, coordinated programme governance structure. The result is consistent safety documentation, coordinated regulatory responses and greater confidence during authority interactions. Our Global CRO capabilities extend that coordination across multinational programs, maintaining consistent safety quality and regulatory alignment across all participating jurisdictions throughout development and the post-marketing lifecycle.
Pharmacovigilance Across Every Phase of Development
Pharmacovigilance priorities evolve as programs advance. Evestia Clinical adapts safety strategies to each phase, from intensive signal oversight in first-in-human studies, through benefit-risk complexity in proof-of-concept programs, to the coordinated multinational safety governance that registration and commercial programs require.
First-in-human studies demand intensive safety oversight. When investigational therapies are administered to humans for the first time, the ability to identify safety signals rapidly and communicate them clearly is paramount. Our teams provide close collaboration with investigators and sponsors, rapid safety reporting and the proactive governance that protects both patients and program momentum in early development.
Learn moreExpanding patient populations and growing safety datasets introduce new complexity in Phase II. Proof-of-concept data drives significant funding decisions, and the safety profile emerging at this stage shapes the design and commercial viability of future registration studies. Our Pharmacovigilance specialists maintain efficient reporting, signal management and benefit-risk oversight throughout dose-ranging and efficacy evaluation programs.
Learn moreLarge multinational registration studies generate significant volumes of safety data across multiple countries, regulatory frameworks and reporting timelines. The regulatory stakes are highest at this stage, and coordinated safety oversight is essential to maintaining compliance, program confidence and submission readiness. Our Global CRO capabilities help sponsors manage complex international safety activities while maintaining consistent quality throughout.
Learn morePost-marketing pharmacovigilance extends safety oversight throughout commercialization, with new safety obligations and ongoing surveillance responsibilities. Our teams provide the case management, signal oversight and aggregate reporting that keep marketed products compliant and commercially credible across the product lifecycle.
Learn morePharmacovigilance Expertise Across Complex Therapeutic Areas
Disease-specific Pharmacovigilance strengthens safety oversight across oncology, rare disease, neurology, immunology, inflammation and cell and gene therapy. Complex safety profiles, immune-mediated events, long-term follow-up obligations and evolving ATMP frameworks require disease-specific knowledge that strengthens signal assessment, risk management planning and alignment with the regulatory expectations of each therapeutic area.
Oncology
Oncology programs involve complex, often overlapping safety profiles and specialized risk management requirements. Immune-mediated toxicities, combination regimens and biomarker-driven eligibility all require safety strategies that go beyond standard adverse event management. Our teams provide pharmacovigilance support tailored to the specific challenges of oncology development across solid tumors, hematological malignancies and immuno-oncology.
Learn moreRare Disease
Rare disease therapies frequently involve small patient populations, limited prior safety data and unique regulatory incentives that require specialist expertise to access and protect. Managing safety activities for orphan drug programs demands careful signal management, close authority engagement and the regulatory knowledge to maintain compliance when population-level data is inherently limited.
Learn moreNeurology
Neurological programs often involve long treatment durations, complex CNS safety considerations and endpoints that are difficult to evaluate without specialist knowledge. Our Pharmacovigilance specialists provide safety oversight aligned with the unique challenges of neurodegenerative and CNS disease development, ensuring long-term safety monitoring is structured, compliant and scientifically sound.
Learn moreImmunology
Immune-mediated adverse events, biologics safety and the specific challenges of autoimmune disease development require specialist pharmacovigilance expertise that generic safety teams cannot provide. Our teams support immunology programs from clinical trial adverse event management through to post-marketing surveillance with the disease-specific knowledge these programs demand.
Learn moreInflammation
Inflammation clinical trials targeting chronic conditions require careful, sustained safety monitoring across extended study durations and complex patient populations. Our Pharmacovigilance specialists provide the structured adverse event management and signal surveillance that inflammation programs require throughout the development and post-marketing lifecycle.
Learn moreCell & Gene Therapy
Advanced therapy medicinal products introduce safety considerations that existing Pharmacovigilance frameworks were not designed to address. Evolving regulatory guidance, long-term follow-up obligations and novel adverse event profiles require specialist expertise. Our teams provide tailored safety solutions built around the specific requirements of ATMP development, from clinical program initiation through to post-marketing surveillance.
Learn moreIntegrated Scientific Capability for Sponsors
Evestia Clinical's integrated scientific capability gives sponsors access to Pharmacovigilance expertise, cross-functional Biometrics support and collaboration across Medical Affairs, Medical Writing, Clinical Data Management and Biostatistics.
This integrated capability supports stronger global safety oversight, consistent regulatory collaboration and the cross-functional program governance that complex therapeutic areas and global development programs require. For sponsors, it means a partner with the depth to support the full clinical development lifecycle from a single, accountable team.
Integrated Pharmacovigilance and Medical Writing Support
Aggregate safety reports require scientific rigor, regulatory precision and consistent messaging across every reporting period. When Pharmacovigilance and Medical Writing work together, safety narratives stay aligned with case-level data, aggregate reports demonstrate a coherent safety profile and regulatory responses reflect one consistent scientific narrative.
Evestia Clinical integrates Pharmacovigilance, Medical Affairs and Medical Writing to strengthen DSUR preparation, PSUR and PBRER quality, safety narrative accuracy and the consistency of regulatory responses across the full product lifecycle. Working alongside Regulatory Affairs, this model ensures every aggregate safety submission is scientifically rigorous, regulatory-compliant and delivered on schedule. For sponsors, it means submission quality, confident authority interactions and consistent safety reporting throughout every reporting cycle, from first-in-human safety reporting through to post-marketing obligations.
Why Sponsors Choose Evestia Clinical for Pharmacovigilance
Therapeutic Area Expertise: Disease-specific medical knowledge strengthens safety oversight across oncology, rare disease, neurology, immunology, inflammation and cell and gene therapy. Physician expertise ensures safety strategies are scientifically appropriate for each program and aligned with the regulatory expectations of each therapeutic area.
Experienced Pharmacovigilance Leadership
Strategic safety leaders strengthen program oversight and regulatory engagement. Sponsors gain direct access to senior PV professionals who provide the regulatory knowledge, governance depth and program continuity that development and post-marketing safety activities require throughout the product lifecycle.
Global Safety Expertise
Coordinated multinational Pharmacovigilance supports consistent reporting and global regulatory confidence. Aligned safety strategies, coordinated reporting timelines and consistent benefit-risk assessments across FDA, EMA, MHRA and other markets give sponsors the international safety governance that global programs require.
Advanced Safety Database Experience
Flexible technology support across Veeva Vault Safety, Oracle Argus Safety and ARIS Global LifeSphere Safety Multivigilance enables sponsors to continue using validated systems without disrupting existing workflows. Operating within sponsor-owned, Evestia-hosted or hybrid environments, the priority is seamless, efficient safety operations throughout the program lifecycle.
Integrated Regulatory Support
Seamless collaboration across Pharmacovigilance, Medical Affairs, Regulatory Affairs and Medical Writing ensures safety documentation, aggregate reports and regulatory submissions are consistent, compliant and submission-ready. Integrated delivery supports aligned submissions, consistent safety messaging and confident regulatory engagement throughout development and post-marketing.
Therapeutic Area Expertise
Disease-specific safety knowledge strengthens safety oversight across oncology, rare disease, neurology, immunology, inflammation and cell and gene therapy. Specialist expertise ensures safety strategies are scientifically appropriate for each program and aligned with the regulatory expectations of each therapeutic area.
Flexible Pharmacovigilance Delivery Models
Sponsors scale Pharmacovigilance support to program requirements without expanding permanent internal infrastructure. PV professionals available through our FSP Solutions model provide embedded safety expertise within sponsor teams, aligning safety capability with program stage and funding milestones.
Flexible Pharmacovigilance Delivery Models
Program complexity, internal team capacity and organizational growth stage all influence the pharmacovigilance model that best serves a sponsor. Evestia Clinical provides flexible delivery options designed to align with where you are in your development journey, structured to evolve as your program and organization grow.
Full-Service Pharmacovigilance
Comprehensive safety management delivered through our integrated Full-Service CRO model, providing a single accountable partner for case processing, signal detection, aggregate reporting and regulatory safety submissions from study initiation through to post-marketing. Well suited to sponsors requiring complete outsourcing of pharmacovigilance functions without managing multiple safety vendors.
Learn moreFunctional Service Provider (FSP) Support
Dedicated pharmacovigilance professionals embedded within sponsor organizations through our Functional Service Provider Solutions model, providing specialist safety resource aligned with internal governance structures for sponsors retaining internal oversight.
Learn moreHybrid Safety Models
Flexible arrangements that combine sponsor-led oversight with specialist external pharmacovigilance expertise, enabling organizations to retain strategic control while accessing additional resource, specialist capabilities or geographic coverage as development programs expand. Particularly valuable for sponsors managing global programs across multiple regulatory environments.
Learn moreThese models allow sponsors to access Pharmacovigilance support aligned with each stage of development and commercialization.
Pharmacovigilance for Biotech Companies
As programs advance, Pharmacovigilance complexity grows alongside safety reporting obligations across expanding markets. Evestia Clinical provides scalable Pharmacovigilance expertise and embedded partnership that grow with each program, supporting biotechnology innovation throughout development and commercialization.
Operating as an extension of sponsor teams, biotech sponsors gain experienced Pharmacovigilance specialists, senior safety leadership and flexible resource aligned with program timelines and funding milestones. Teams engage proactively throughout development, building program knowledge that anticipates safety considerations and supports confident benefit-risk decisions.
Whether accessed through our Full-Service CRO model or through embedded specialists via FSP Solutions, our safety teams integrate within sponsor governance structures to provide the strategic capability that complex programs need. From first-in-human Phase I safety reporting through to commercial readiness and post-marketing surveillance, Evestia Clinical delivers Pharmacovigilance designed around the realities of biotechnology development.
Frequently Asked Questions About Pharmacovigilance
Explore Related Clinical Development Services
Service Pages
Development Phases
Pharmacovigilance That Supports Confident Clinical Development
Pharmacovigilance specialists, integrated safety oversight and global regulatory expertise give sponsors the confidence to advance programs from first-in-human studies through to commercialization. Safety strategy built around partnership,
integrated support and product lifecycle expertise.
Whether through full-service Pharmacovigilance, specialist expertise through our FSP Solutions model or integrated safety and clinical development guidance through our Biotech CRO services, Evestia Clinical provides partnership, flexible delivery and product lifecycle expertise that complex programs require.